Drug Trial Radar · NCT06874010
A Multiple Ascending Dose Study of DT-216P2 in Patients With Friedreich's Ataxia
Last checked: Nov 20, 2026Latest source record: May 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Jun 2025
Primary completion
Dec 2026
Study completion Mar 2027
Sponsor
- Lead sponsor
- Design Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 13, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and tolerability, and pharmacokinetics of DT-216P2 administered multiple ascending doses in patients with FA.
Conditions
- Friedreich Ataxia
Interventions
DT-216P2Drug
Active
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency of treatment-emergent adverse events (TEAE)Time frame: Up to Week 12
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Scientia Clinical Research Ltd
Sydney, New South Wales, Australia · Recruiting
Doherty Clinical Trials
East Melbourne, Victoria, Australia · Recruiting
Nucleus Network
Melbourne, Victoria, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.